Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994:(573):57-60.

Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections

Affiliations
  • PMID: 7524797
Clinical Trial

Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections

K H Vestweber et al. Eur J Surg Suppl. 1994.

Abstract

Intra-abdominal infections are a serious problem for surgeons. Treatment consists of a combination of operation, antimicrobial treatment, and supportive measures. beta-Lactam antibiotics have a major role in the treatment of peritonitis, and in combination with beta-lactamase inhibitors, the penicillins have an even larger part to play than previously. A multicentre prospective trial to evaluate the efficacy and safety of piperacillin/tazobactam in the treatment of serious intra-abdominal infections was conducted in Europe. One hundred and six evaluable patients with documented intra-abdominal infections were treated with piperacillin 4 g/tazobactam 500 mg every eight hours. The most common diagnoses were peritonitis, intra-abdominal abscess, and complicated diverticulitis. A 90% favourable clinical response rate (cured/improved) was found during the first two weeks of treatment. Piperacillin/tazobactam was extremely active against the Gram-negative aerobic, Gram-positive aerobic, and anaerobic bacteria isolated in this trial. Overall, the drug was well tolerated and the side effects were minimal.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources